Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is associated with a particularly poor prognosis, as reflected by the five-year relative survival rate of only 13% for pancreatic cancer in the United States (3% for distant-stage disease), which contrasts sharply with the higher survival rates observed in breast cancer (91%), prostate cancer (97%), and colon cancer (63%). Despite advances in therapies, PDAC outcomes remain poor due to its complex tumor microenvironment (TME), characterized by immune-stromal interactions that drive progression and immunosuppression. Key cytokines like interleukins promote fibrosis and tumor growth, while growth factors enhance invasiveness and therapy resistance. Interferons, Tumor necrosis factors, and Colony-stimulating factors modulate immune responses, and chemokines orchestrate immune cell trafficking and metastasis. These components collectively create a fibrotic, immunosuppressive niche that hinders treatment efficacy. Emerging therapeutic strategies aim to disrupt TME-related pathways, such as cytokine/chemokine inhibition, stromal reprogramming, and immune checkpoint modulation. Combining targeted TME therapies with chemotherapy or immunotherapy shows promise in overcoming resistance. This review explores the interplay of cytokines, immune dynamics, and stromal signaling in PDAC, highlighting novel therapeutic approaches to improve clinical outcomes by reshaping the TME.
No takes yet. Share an insight, caveat, or question.
Chi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: